The clinical pharmacology of VM26 and VP16-213

This publication has 24 references indexed in Scilit:

• Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography
  Journal of Chromatography B: Biomedical Sciences and Applications, 1980
• Podophyllotoxin derivative VP 16-213
  Cancer Chemotherapy and Pharmacology, 1979
• Etoposide (VP-16-213)
  Cancer Treatment Reviews, 1979
• VP-16-213 MONOTHERAPY FOR REMISSION INDUCTION OF SMALL CELL LUNG-CANCER - RANDOMIZED TRIAL USING 3 DOSAGE SCHEDULES
  1978
• The Role of Drug Disposition Kinetics on Cellular Transport of the Antineoplastic Agent VM-26
  Drug Metabolism Reviews, 1978
• VM 26 and VP 16–213: A comparative analysis
  Cancer, 1977
• PHASE I CLINICAL-TRIAL OF AN ORAL SOLUTION OF VP-16-213
  1976
• Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives
  European Journal of Cancer (1965), 1975
• PTG, a new antineoplastic epipodophyllotoxin
  Clinical Pharmacology & Therapeutics, 1975
• Phase I clinical trial of a new antitumor agent, 4'-demethylepipodophyllotoxin 9-(4,6-O-ethylidene- -D-glucopyranoside) (NSC-141540; VP-16-213).
  1972